GSK Bets Big On Its B7-H4 ADC With Five Phase III Trials Upcoming
The UK drugmaker thinks it could have another blockbuster drug on its hands with GSK going all in on its antibody-drug conjugate, Mo-Rez.
Scrip - April 12, 2026

UMSOM Researcher To Drive Innovation By Making New Cervix ‘Organ-On-A-Chip’ Widely Accessible
Researchers at the University of Maryland School of Medicine developed a cervical organ-on-a-chip model that will be accessible to all researchers. Lead researcher Jacques Ravel believes that this model will drive innovation and new treatments for STIs in women.
Medtech Insight - April 10, 2026

Global Medtech Guidance Tracker: March 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 80 documents have been posted on the tracker since its last update.
Medtech Insight - April 10, 2026

Medline Recalls Millions Of Angiographic Syringes After FDA Warning Letter
Medline is recalling millions of Namic angiographic control syringes after reports of serious injury. The recall follows a warning letter the company received from the FDA after an inspection of its New York facility.
Medtech Insight - April 10, 2026

Boehringer Hands CT-155 Commercial Rights To Click Therapeutics In $50M Deal Restructure
A five-year partnership for a schizophrenia digital therapeutic has been restructured in a way that tells a broader story: Now Click Therapeutics will take full responsibility for CT-155’s commercialization, backed by a $50m Series D investment and continued clinical collaboration.
Medtech Insight - April 10, 2026

Direct-To-Consumer Advertising, IND Reform Top US FDA’s Wish List For Statutory Changes
Legislative proposals in FDA's FY 2027 budget request include updating agency’s authorities over direct-to-consumer advertising for brand and compounded drugs and creating a new expedited IND pathway.
HBW Insight - April 12, 2026

Organon Rumors Persist Despite Sun’s Fresh Denial
Sun Pharma reiterates that Organon deal reports are “speculative” even as detailed claims of a $12bn bid process unsettle investors, highlighting the potential for a transformational but highly leveraged and strategically complex acquisition.
Generics Bulletin - April 10, 2026

Outlook Goes After FDA With Formal Dispute Resolution Request
Outlook will be meeting again with the FDA to discuss the approval of its ophthalmic formulation of bevacizumab. However, this time, Outlook will go through a different procedural pathway.
Generics Bulletin - April 10, 2026

‘The Number One Priority Is Sustainable Access’ – AAM Chair Hoffman On Stabilizing The US Industry
Fresh from taking over the role of AAM chair, Lupin’s Bob Hoffman talks to Generics Bulletin about how the “squeezed” US off-patent industry is having to work hard just to remain sustainable – and the messages that US policymakers need to hear.
Generics Bulletin - April 10, 2026

GTCR Takeover Fuels Zentiva Expansion Across European Markets
GTCR has closed its acquisition of Zentiva, backing further expansion in generics, biosimilars and consumer health as the European off-patent sector faces rising policy focus on supply security, affordability and sustainability.
Generics Bulletin - April 10, 2026

Deals Shaping The Industry, March 2026
An interactive look at pharma, medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
In Vivo - April 9, 2026

Podcast: How Israel Is Positioning Itself As A Global Innovation Hub
AION Labs CEO Mati Gill on why Israel - despite active conflict - is emerging as a serious AI-native drug discovery hub for global pharma.
In Vivo - April 9, 2026